On Wednesday, Following U.S. Stocks were among the “Top Losers”: QUALCOMM Incorporated, (NASDAQ:QCOM), iBio, (NYSEMKT:IBIO), Hercules Offshore, (NASDAQ:HERO), Biocept, (NASDAQ:BIOC)
QUALCOMM Incorporated, (NASDAQ:QCOM), with shares dwindled -2.25%, closed at $70.27.
iBio, (NYSEMKT:IBIO), with shares declined -6.12%, settled at $0.69.
Hercules Offshore, (NASDAQ:HERO), with shares dipped -5.96%, and closed at $0.47.
Biocept, (NASDAQ:BIOC), dropped -5.92%, and closed at $3.18.
Latest NEWS regarding these Stocks are depicted underneath:
QUALCOMM Incorporated (NASDAQ:QCOM)
QUALCOMM Incorporated (QCOM), declared that its Board of Directors has approved a major raise in the Corporation’s capital return program to deliver value for stockholders. Effective right away, the Board has authorized the Corporation to repurchase up to $15 billion of its ordinary stock. The $15 billion program replaces the previous program, which had a $2.1 billion authorization remaining.
Qualcomm intends to repurchase $10 billion of its ordinary stock within about twelve months of the date of this declaration, in addition to its current commitment to return a minimum of 75% of its free cash flow to stockholders through stock repurchases and dividends.
The Board also approved a 14 percent raise in Qualcomm’s quarterly cash dividend, raising the annualized dividend payout to $1.92 per share of ordinary stock. The cash dividend will raise from $0.42 to $0.48 per share of ordinary stock and will be effective for quarterly dividends payable after March 25, 2015. The Corporation plans to finance the capital return program primarily by accessing the public debt markets in 2015.
“Our business continues to generate substantial operating cash flow, and today’s declaration represents an important step in returning that cash to our owners while still preserving the planned flexibility needed to drive stockholder value through growth,” said Steve Mollenkopf, CEO of Qualcomm Incorporated. “I am happy that we continue to build on our track record of returning capital to stockholders, having exceeded each of our capital return commitments in 2014 and returned about $37 billion to stockholders since these programs began in 2003.”
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States.
iBio, Inc. (NYSEMKT:IBIO)
If we look into the history, then Formerly on February 25, iBio, Inc. (IBIO), declared the issue of US patent serial No. 8,962,278 titled “COMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINS.” The patent will join patent family members formerly issued in China, India, Korea and Europe.
Formerly on February 12, a leader in plant-based biotechnology for developing and manufacturing biological products, declared the issuance of additional patents in the US and Europe covering novel plant viral vector-based protein expression technologies.
iBio, Inc., a biotechnology corporation, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally.
Hercules Offshore, Inc. (NASDAQ:HERO)
Formerly on February 26, Hercules Offshore, Inc. (HERO), declared that it has received a notice from Saudi Aramco terminating its drilling contract for the Hercules 261, effective March 27, 2015. The Corporation is in the process of seeking a basis for ongoing the Hercules 261 contract. As formerly revealed, the Corporation has been in discussions with Saudi Aramco about a possible rate reduction on the Hercules 262 and Hercules 266. The Corporation has not received a notice of termination from Saudi Aramco with respect to these rigs.
Formerly on Feb. 19, a range of services provider company to oil and gas producers, declared that it has published the February Fleet Status Report (“the Report”). The Report comprises the Hercules Offshore Rig Fleet Status (as of February 19, 2015), which contains detailed contract information for each of the Corporation’s drilling rigs. The Report also comprises the Hercules Offshore Liftboat Fleet Status Report, which contains information by liftboat class for January 2015, counting proceed per day and operating days.
Hercules Offshore, Inc., together with its auxiliaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide.
Biocept, Inc. (NASDAQ:BIOC)
Biocept, Inc. (BIOC), a molecular oncology diagnostics corporation specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), declared the launch of its EGFR mutation detection testing utilizing a patient’s blood-based liquid biopsy. This innovative diagnostic has the potential to assist physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments.
The identification of these mutations in patients with advanced NSCLC can provide them with the opportunity to receive optimal targeted therapies, known as Tyrosine Kinase Inhibitors (TKIs). In the United States, there are two FDA-approved TKI therapies for patients with specific EGFR mutations: Erlotinib, marketed as Tarceva(R) by Genentech, Inc.; and Afatinib, marketed as Gilotrif(R) by Boehringher Ingelheim GmbH.
Lung cancer is the leading cause of cancer-related death among men and women. According to data from the National Cancer Institute in 2013, an estimated 228,190 Americans will be diagnosed with lung cancer, and 159,480 would die from the disease. About 85 percent of lung cancers are non-small cell lung cancers (NSCLC), making it the most ordinary type of lung cancer. EGFR gene mutations are present in the tumors of about 10 percent of NSCLC patients, with the majority of these gene mutations expressing EGFR in exon 19 deletions or exon 21 L858R substitutions.
Biocept, Inc., a cancer diagnostics corporation, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
